Fennec Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2015
Net Income	-	-16.05	-23.71	-17.35	-18.11	Upgrade
Other Amortization	-	0.29	0.15	0.02	0.4	Upgrade
Loss (Gain) From Sale of Investments	-	0.04	0.18	0.03	-0.1	Upgrade
Stock-Based Compensation	-	5.35	4.22	4.01	2.88	Upgrade
Change in Accounts Receivable	-	-7.27	-1.55	-	-	Upgrade
Change in Inventory	-	-1.58	-0.58	-	-	Upgrade
Change in Accounts Payable	-	1.39	1.61	-0.79	-0.04	Upgrade
Change in Other Net Operating Assets	-	0.68	1.61	-0.14	-0.62	Upgrade
Operating Cash Flow	-	-17.14	-18.06	-14.22	-15.6	Upgrade
Long-Term Debt Issued	-	5	25.17	5	-	Upgrade
Long-Term Debt Repaid	-	-	-5	-0.01	-	Upgrade
Net Debt Issued (Repaid)	-	5	20.17	4.99	-	Upgrade
Issuance of Common Stock	-	1.72	0.93	0.03	32.43	Upgrade
Repurchase of Common Stock	-	-0.08	-0.19	-	-	Upgrade
Other Financing Activities	-	-	-0.18	-0.04	-0.14	Upgrade
Financing Cash Flow	-	6.64	20.73	4.98	32.29	Upgrade
Net Cash Flow	-	-10.51	2.67	-9.24	16.69	Upgrade
Levered Free Cash Flow	-	-12.35	-9.17	-7.73	-8.92	Upgrade
Unlevered Free Cash Flow	-	-10.34	-8.61	-7.66	-9.07	Upgrade
Change in Net Working Capital	5.03	7.71	-1.29	0.91	0.76	Upgrade

Updated Mar 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q